About InSure® ONE™
Early detection for a preventable cancer
Colorectal cancer that is caught in the early stages has a 5-year survival rate of over 90%.1 Yet, only 39% of cases2 are diagnosed in early stages due to low screening rates. When disease spreads to distant organs, the 5-year survival rate drops to 11%.3
InSure® ONE™ is a convenient, at-home fecal immunochemical test (FIT) kit that only requires water-based sampling of one bowel movement. Colorectal cancer screening has never been easier. Reach more patients with InSure® ONE™.
Only 39% of cases2
are diagnosed in early stages due to low screening
Dramatic decrease in new colorectal cancer diagnosis during COVID-19
Accurate colorectal screening
InSure® ONE™ qualitatively detects human hemoglobin from blood in fecal samples,5 which may be an indication of lower gastrointestinal bleeding associated with disorders such as diverticulitis, ulcerative colitis, polyps, colorectal cancers, or large adenomas that bleed. The assay uses monoclonal antibodies to capture human hemoglobin on a test strip. Studies show that the InSure® ONE™ testing helps more people actually get the screening they need. FIT testing is supported by medical guidelines, including the American Cancer Society, the American College of Gastroenterology, and the US Preventive Services Task Force for early detection of Colorectal Cancer.3-5
What’s in the kit
InSure® ONE™ comes in a patient-friendly kit that contains everything necessary to collect a water-based sample and package it for shipping in an enclosed self-mailing envelope.
The kit includes
Improve kit return rates
As a leader in colorectal cancer screening, we know that every kit returned could save a life by early detection. Our InSure ONE integrated reminder program helps encourage test compliance by sending reminder messages to patients to complete and return their collection kits. Electronic orders for InSure ONE placed in Quanum® Lab Services Manager or your EMR interface are eligible to receive reminders.
The convenient water-based collection method uses unique, patented brush sampling that doesn’t require any stool collection or handling. There are no dietary or medicinal restrictions. Patients collect 2 water-based samples from a single bowel movement. This patient-friendly approach to testing is associated with up to 66% greater patient compliance.7
Please contact your Quest Diagnostics representative for instructions in additional languages.
How to get started
Start ordering InSure ONE kits using Quanum® Lab Services Manager. If you don’t have a Quanum account, create one in less than 5 minutes by clicking here. If you would prefer to order kits over the phone, please call 1.866.MY.QUEST (1.866.697.8378) and state “supplies” upon connection for assistance.
Search for test code 11290 for InSure ONE kits, where you will find all patient instructions for specimen collection and for returning completed test kits.
Quest will ship the kits to your practice at no cost, based on usage and test completion.
Distribute kits to average-risk patients aged 45+ during annual wellness visits. A completed requisition form from Quanum® Lab Services Manager or your EMR should be printed and placed in the business reply envelope found inside the test kit envelope prior to the patient leaving the office.
Not familiar with Quanum® Lab Services Manager? You can sign up for an account at enroll.quanumsolutions.com/enrollment
Order InSure ONE in just 2 easy steps
Test ordering information
|Test name||Test code||CPT code(s)*|
|Fecal Globin by Immunochemistry (InSure®)||11290||82274 (HCPCS:G0328)|
*The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions to the payer being billed.
- Altekruse SF, Kosary CL, Krapcho M, et al (eds). SEER 18 2010–2016, All Races, Both Sexes by SEER Summary Stage 2000. Accessed July 31, 2020. https://seer.cancer.gov/statfacts/html/colorect.html
- American Cancer Society. Colorectal Cancer Facts & Figures 2017-2019. Published 2017. Accessed July 31, 2020. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/colorectal-cancer-facts-and-figures/colorectal-cancer-facts-and-figures-2017-2019.pdf
- InSure® ONE™. K170548 – Instructions for use. Quest Diagnostics; 2017.
- InSure® FIT. F002457 Fecal immunochemical test immunoassay for human hemoglobin in stool. Product instructions. Enterix; 2011.
- Screening for colorectal cancer: US Preventive Services Task Force recommendation statement. JAMA. 2016;315(23):2564-2575. doi:10.1001/jama.2016.5989
- Rex DK, Boland CR, Dominitz JA, et al. Colorectal cancer screening: recommendations for physicians and patients from the U.S. Multi-Society Task Force on Colorectal Cancer. Am J Gastroenterol. 2017;112(7):1016-1030. doi:10.1038/ajg.2017.174
- Cole SR, Young GP, Esterman A, Cadd B, Morcom J. A randomised trial of the impact of new faecal haemoglobin test technologies on population participation in screening for colorectal cancer. J Med Screen. 2003;10(3):117-122.